Search Browse Earnings

CASI Pharmaceuticals, Inc. — SlamSEC

CASI Pharmaceuticals, Inc.

OTC:CASIF

Pharmaceutical Preparations·BEIJING, F4

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Revenue

$38.0M

+26.7% YoY

FY 2024

Adj. EBITDA

-$32.8M

-86.3% margin

FY 2024

Net Income

-$41.0M

-107.8% margin

FY 2024

EPS (Diluted)

-$3.01

FY 2024

Stock Price

$0.23

-71.7%

2026-02-25

52W Range

$0.21 – $3.09

P/E Ratio

-0.1x

Market Cap

$3.5M

Cash

$17.1M

FY 2024

Total Debt

$18.9M

FY 2024

Net Debt

$1.8M

FY 2024

Enterprise Value

$5.3M

Debt / EBITDA

-0.1x

FY 2024

EV / EBITDA

-0.2x

Employees

—